Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia

Research output: Contribution to journalArticle

Abstract

Introduction: Patients with hemophilia now have a life expectancy very close to that of the unaffected male population and, hence, are at risk of developing the classic age-related morbidities, i.e., cardiovascular diseases. The peculiarity of the management of these diseases in hemophilia is that antithrombotic drugs impinge on the already compromised hemostasis of these lifelong bleeders. Areas covered: This opinion article outlines the strategies we have developed, based on our clinical experience, for the antithrombotic treatment of two common cardiovascular diseases acute coronary syndromes and chronic atrial fibrillation in patients with hemophilia A and B. Expert opinion: In the absence of specific evidence-based guidelines for patients with coagulation defects, antithrombotic treatment is currently based on expertise and adaptation of the guidelines developed for non-hemophilic patients. Replacement therapy should be tailored with the deficient coagulation factor so as to control the increased risk of bleeding inherent in the use of antiplatelet and anticoagulant drugs.

Original languageEnglish
Pages (from-to)505-510
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number4
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Hemophilia A
Acute Coronary Syndrome
Atrial Fibrillation
Cardiovascular Diseases
Guidelines
Hemophilia B
Blood Coagulation Factors
Platelet Aggregation Inhibitors
Expert Testimony
Therapeutics
Disease Management
Life Expectancy
Hemostasis
Anticoagulants
Hemorrhage
Morbidity
Pharmaceutical Preparations

Keywords

  • Acute coronary syndromes
  • Anticoagulant therapy
  • Antiplatelet therapy
  • Atrial fibrillation
  • Hemophilia A
  • Hemophilia B

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

@article{229635abf0e04db5a69819d62a325e22,
title = "Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia",
abstract = "Introduction: Patients with hemophilia now have a life expectancy very close to that of the unaffected male population and, hence, are at risk of developing the classic age-related morbidities, i.e., cardiovascular diseases. The peculiarity of the management of these diseases in hemophilia is that antithrombotic drugs impinge on the already compromised hemostasis of these lifelong bleeders. Areas covered: This opinion article outlines the strategies we have developed, based on our clinical experience, for the antithrombotic treatment of two common cardiovascular diseases acute coronary syndromes and chronic atrial fibrillation in patients with hemophilia A and B. Expert opinion: In the absence of specific evidence-based guidelines for patients with coagulation defects, antithrombotic treatment is currently based on expertise and adaptation of the guidelines developed for non-hemophilic patients. Replacement therapy should be tailored with the deficient coagulation factor so as to control the increased risk of bleeding inherent in the use of antiplatelet and anticoagulant drugs.",
keywords = "Acute coronary syndromes, Anticoagulant therapy, Antiplatelet therapy, Atrial fibrillation, Hemophilia A, Hemophilia B",
author = "Mannucci, {Pier Mannuccio}",
year = "2012",
month = "3",
doi = "10.1517/14656566.2012.656591",
language = "English",
volume = "13",
pages = "505--510",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia

AU - Mannucci, Pier Mannuccio

PY - 2012/3

Y1 - 2012/3

N2 - Introduction: Patients with hemophilia now have a life expectancy very close to that of the unaffected male population and, hence, are at risk of developing the classic age-related morbidities, i.e., cardiovascular diseases. The peculiarity of the management of these diseases in hemophilia is that antithrombotic drugs impinge on the already compromised hemostasis of these lifelong bleeders. Areas covered: This opinion article outlines the strategies we have developed, based on our clinical experience, for the antithrombotic treatment of two common cardiovascular diseases acute coronary syndromes and chronic atrial fibrillation in patients with hemophilia A and B. Expert opinion: In the absence of specific evidence-based guidelines for patients with coagulation defects, antithrombotic treatment is currently based on expertise and adaptation of the guidelines developed for non-hemophilic patients. Replacement therapy should be tailored with the deficient coagulation factor so as to control the increased risk of bleeding inherent in the use of antiplatelet and anticoagulant drugs.

AB - Introduction: Patients with hemophilia now have a life expectancy very close to that of the unaffected male population and, hence, are at risk of developing the classic age-related morbidities, i.e., cardiovascular diseases. The peculiarity of the management of these diseases in hemophilia is that antithrombotic drugs impinge on the already compromised hemostasis of these lifelong bleeders. Areas covered: This opinion article outlines the strategies we have developed, based on our clinical experience, for the antithrombotic treatment of two common cardiovascular diseases acute coronary syndromes and chronic atrial fibrillation in patients with hemophilia A and B. Expert opinion: In the absence of specific evidence-based guidelines for patients with coagulation defects, antithrombotic treatment is currently based on expertise and adaptation of the guidelines developed for non-hemophilic patients. Replacement therapy should be tailored with the deficient coagulation factor so as to control the increased risk of bleeding inherent in the use of antiplatelet and anticoagulant drugs.

KW - Acute coronary syndromes

KW - Anticoagulant therapy

KW - Antiplatelet therapy

KW - Atrial fibrillation

KW - Hemophilia A

KW - Hemophilia B

UR - http://www.scopus.com/inward/record.url?scp=84857245676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857245676&partnerID=8YFLogxK

U2 - 10.1517/14656566.2012.656591

DO - 10.1517/14656566.2012.656591

M3 - Article

C2 - 22332913

AN - SCOPUS:84857245676

VL - 13

SP - 505

EP - 510

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 4

ER -